- Home
- MIY vs CAPR Comparison
MIY vs CAPR Comparison
Compare MIY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIY
- CAPR
- Stock Information
- Founded
- MIY 1992
- CAPR 2005
- Country
- MIY United States
- CAPR United States
- Employees
- MIY N/A
- CAPR N/A
- Industry
- MIY Investment Bankers/Brokers/Service
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIY Finance
- CAPR Health Care
- Exchange
- MIY Nasdaq
- CAPR Nasdaq
- Market Cap
- MIY 321.2M
- CAPR 324.6M
- IPO Year
- MIY N/A
- CAPR N/A
- Fundamental
- Price
- MIY $11.17
- CAPR $6.28
- Analyst Decision
- MIY
- CAPR Strong Buy
- Analyst Count
- MIY 0
- CAPR 8
- Target Price
- MIY N/A
- CAPR $24.75
- AVG Volume (30 Days)
- MIY 56.8K
- CAPR 1.4M
- Earning Date
- MIY 01-01-0001
- CAPR 08-11-2025
- Dividend Yield
- MIY 3.98%
- CAPR N/A
- EPS Growth
- MIY N/A
- CAPR N/A
- EPS
- MIY N/A
- CAPR N/A
- Revenue
- MIY N/A
- CAPR $13,392,150.00
- Revenue This Year
- MIY N/A
- CAPR N/A
- Revenue Next Year
- MIY N/A
- CAPR $6,061.53
- P/E Ratio
- MIY N/A
- CAPR N/A
- Revenue Growth
- MIY N/A
- CAPR N/A
- 52 Week Low
- MIY $9.45
- CAPR $3.98
- 52 Week High
- MIY $11.70
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- MIY 58.77
- CAPR 36.33
- Support Level
- MIY $11.07
- CAPR $6.17
- Resistance Level
- MIY $11.24
- CAPR $7.30
- Average True Range (ATR)
- MIY 0.11
- CAPR 0.43
- MACD
- MIY -0.00
- CAPR -0.11
- Stochastic Oscillator
- MIY 73.53
- CAPR 4.53
About MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.